July 20, 2026 11:20 AM EDT News Briefing Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromab ENDPOINTS Scribe writes in $96M IPO: The gene editing biotech expects net proceeds of about $96 million if it prices its … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
74 words · extracted 1d agoread original ↗
comments(0)
5-min edit window · permanent after that